

Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on DOAC

NCT06241677

Status	RECRUITING
Phase	Not Applicable
Sponsor	Chinese University of Hong Kong
Enrollment	260 participants

Key Eligibility Criteria

Inclusion (6)

- Acute ischemic stroke patients with a last-known-well to presentation time within 4.5 hours
- Patients who took any doses of apixaban (2.5mg or 5mg twice daily), dabigatran (110mg or 150mg twice daily), edoxaban (30mg or 60mg daily) or rivaroxaban (15mg or 20mg daily) 12-48 hours before presentation
- National Institute of Health Stroke Scale (NIHSS) e 3
- Alberta Stroke Programme Early CT (ASPECT) score e 6
- Pre-morbid modified Rankin Scale (mRS) d 3
- ... and 1 more (see full listing online)

Exclusion (5)

- Initial CT brain showing intracranial haemorrhage
- Contraindications to IVT according to current guideline recommendations [5], except for the use of DOAC within 12-48 hours
- Patients with an estimated glomerular filtration rate of ≤ 30 ml/min/1.73m²
- Patients with bleeding propensities apart from the use of DOAC, e.g. platelet count of $< 100 \times 10^9/L$
- Patients with significant head injury immediately prior to presentation

Locations (1 total)

Chinese University of Hong Kong, Hong Kong, Hong Kong